Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases

Table 1 Study population characteristics of included trials

Ref.	Country	Group	No. of patients	M/F	Age (yr)	No. of lesions	Interval between Bev-treatment and surgery	MR
D'Angelica et al[8]	United States	Bev –	32	9/23	51 (34-77)1	1 (1-11)1	-	17
		Bev +	16	-	-	-	6.9 (3-15) wk1	-
Reddy et al[9]	United States	Bev –	57	37/20	60 (51-68)1	2 (1-4)1	-	39
		Bev +	39	25/14	55 (49-64)1	2 (1-3)1	10 (8-13) wk1	27
Mahfud et al[10]	Multicenter	Bev –	45	19/26	62 (59-65)1	6 (3-8)1	-	25
		Bev +	45	31/14	58 (54-61)1	4 (3-5)1	9 wk1	19
Ribero et al[15]	United States	Bev –	43	26/17	57 (26-80)1	2 (1-8)1	-	-
		Bev +	62	36/26	53.5 (34-85)1	2 (1-21)1	≥ 6 wk	-
Kesmodel et al[16]	United States	Bev –	44	30/14	58 (31-80)1	2 (1-9)1	-	30
		Bev +	81	48/33	57 (29-84)1	3 (1-31)1	58 (31-117) d1	47
Zorzi et al[17]	United States	Bev –	13	-	-	-	-	-
		Bev +	19	-	-	-	-	-
Aussilhou et al[18]	France	Bev –	20	-	-	-	-	20
		Bev +	11	-	-	-	-	9
Klinger et al[19]	Austria	Bev –	50	34/16	62.41	-	-	-
		Bev +	56	32/24	63.01	-	2-5 wk	-
Pessaux et al[20]	France	Bev –	21	13/8	63.3 ± 11.72	3 ± 32	-	4
		Bev +	21	10/11	65 ± 8.22	3.8 ± 2.52	11.7 ± 4.7 wk2	5
Rubbia-Brandt et al[21]	Multicenter	Bev –	204	-	-	-	-	-
		Bev +	70	-	-	-	-	-
Tamandl et al[22]	Austria	Bev –	112	35/77	63.6 (28.9-84.2)1	2 (1-10)1	-	17
		Bev +	102	39/63	63.3 (31.4-81.6)1	2 (1-10)1	34 (17-99) d1	28
Wicherts et al[23]	Multicenter	Bev –	97	61/36	62 ± 112	4.5 ± 4.62	-	38
		Bev +	67	42/25	58 ± 112	5.6 ± 4.52	8 (3-19) wk1	31
van der Pool et al[24]	The Netherlands	Bev –	53	33/20	62 (41-79)1	3 (1-7)1	-	14
		Bev +	51	29/22	64 (41-77)1	2 (1-8)1	11 (5-38) wk1	9

M: Male; F: Female; MR: Major resections (≥ segments).

¹Median (range);

²Mean.

Table 2 Results of meta-analysis

Outcome of interest	No. of studies	No. of patients	OR	95%CI	P-value	I2(%)
Overall morbidity	10[8-10,16-18,20,22-24]	Bev + = 452, Bev - = 494	1.17	1.00, 1.37	0.06	0
Severe complication	8[8-10,16,17,20,22,23]	Bev + = 390, Bev - = 421	1.57	0.97, 2.53	0.07	18
Wound complication	6[8-10,16,22,23]	Bev + = 269, Bev - = 296	1.43	0.82, 2.50	0.21	0
Bleeding/thromboembolic complication	5[8-10,23,24]	Bev + = 218, Bev - = 284	0.99	0.41, 2.38	0.98	0
Cardiovascular complication	2[16,23]	Bev + = 148, Bev - = 141	1.14	0.23, 5.56	0.88	0
Pulmonary complication	6[8,16,18,20,23,24]	Bev + = 247, Bev - = 267	1.10	0.60, 2.02	0.77	0
Renal or urinary complication	6[8,16,18,20,23,24]	Bev + = 247, Bev - = 267	0.73	0.24, 2.23	0.58	0
Hepatic dysfunction	5[16-18,20,23]	Bev + = 223, Bev - = 219	0.48	0.22, 1.05	0.07	0
Mortality	10[8-10,16-18,20,22-24]	Bev + = 452, Bev - = 494	0.63	0.16, 2.56	0.52	0
Overall sinusoidal dilation	6[15,19-21,23,24]	Bev + = 265, Bev - = 395	0.53	0.38, 0.75	< 0.001	0
Moderate or severe sinusoidal dilation	6[15,18-21,24]	Bev + = 267,Bev - = 387	0.34	0.19,0.64	< 0.001	46

OR: Odds ratio; Bev: Bevacizumab.